DTC Ads Should Cite Range Of Treatment Options, Blue Cross Assoc. Tells FDA
Executive Summary
Direct-to-consumer advertising should include disclosures to note when a particular drug is one of a range of available treatment choices, the Blue Cross and Blue Shield Association said in comments to FDA
You may also be interested in...
FDA Press Release Policy Restricts Free Speech, Needs Revision – PhRMA
FDA should reconsider its policies restricting language in press releases on unapproved drug uses in light of First Amendment rights, the Pharmaceutical Research & Manufacturers of America maintains in comments to the agency
FDA Commercial Speech Restrictions Could Hold Up In Court, Agency Says
FDA could still enforce restrictions on commercial speech even in light of the recent Supreme Court decision striking down limits on pharmacy advertising of compounding, FDA Associate Chief Counsel Patricia Kaeding said
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011